Ranbaxy concludes deal with Daiichi
November 7th, 2008 - 5:25 pm ICT by IANSNew Delhi, Nov 7 (IANS) Indian pharma major Ranbaxy Laboratories has completed its deal with the Japanese pharma company Daiichi Sankyo, the two companies said Friday. In a regulatory statement, the companies announced the closure of the transformational deal with the execution of the final transfer of the remaining equity shares of the promoters, the Singh family, in Ranbaxy to the Japanese firm.
With this, Daiichi has now acquired 63.92 percent of the equity share capital of Ranbaxy.
As a result of this acquisition, the Singh family has ceased to be promoters of Ranbaxy with effect from Friday.
India’s largest pharmaceutical major Ranbaxy Laboratories officially became a subsidiary of Daiichi Sankyo Oct 20.
Ranbaxy earlier had received $736 million or Rs.35.85 billion through the preferential issue of equity shares and warrants, the two companies said in the joint statement.
Ranbaxy will continue to operate as an independent and autonomous company under Malvinder Mohan Singh, its former chief executive-promoter, despite being a Daiichi Sankyo subsidiary.
Singh will also become a part of Daiichi’s senior global management.
- Daiichi completes acquisition of Ranbaxy - Oct 20, 2008
- Daiichi eyes Ranbaxy for expanding in Africa, Latin America - Mar 12, 2010
- Fortis offers to buy Parkway, deal size at $2.3 bn - Jul 01, 2010
- Ranbaxy settles issue with US health regulator - Dec 21, 2011
- Daiichi says Ranbaxy acquisition will hit its bottomline - Jan 05, 2009
- Ranbaxy's Malvinder Singh is now its chairman - Dec 19, 2008
- Malvinder Singh steps down as Ranbaxy chief executive - May 24, 2009
- Competition check for FDI in pharma will help consumers: CUTS - Oct 11, 2011
- Payments on Ranbaxy open offer concluded: Daiichi Sankyo - Oct 17, 2008
- Japan's Daiichi to buy majority stake in India's Ranbaxy for $4.6 bn (Second Lead) - Jun 12, 2008
- Malvinder Singh steps down as Ranbaxy's chief executive (Lead) - May 24, 2009
- Ranbaxy posts $210 mn net profit - May 11, 2010
- Parkway stake makes Fortis largest Asian hospital chain - Mar 12, 2010
- Ranbaxy incurs Rs.49 million loss in third quarter (Lead) - Oct 31, 2008
- Daiichi to pay Rs.737 per Ranbaxy share in open offer - Aug 11, 2008
Tags: daiichi sankyo, equity share capital, global management, japanese firm, japanese pharma company, mohan singh, preferential issue, promoter, promoters, ranbaxy laboratories
